PROFUSA, INC. Deferred Federal Income Tax Expense (Benefit)
PROFUSA, INC. (PFSA) reported Deferred Federal Income Tax Expense (Benefit) of -$3.75 million for the 12-month period ending 2025-12-31, per its S-1/A filed 2026-05-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-05-01
- PROFUSA, INC. deferred federal income tax expense (benefit) for fiscal 2023 was -$226.99K.
- PROFUSA, INC. deferred federal income tax expense (benefit) for fiscal 2022 was -$187.44K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 8 month | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -$3.75M S-1/A · filed 2026-05-01 | ||
| 2024-12-31 | -$1.61M S-1/A · filed 2026-05-01 | -$271.94K 10-K · filed 2025-03-31 | |
| 2023-12-31 | -$226.99K 10-K · filed 2025-03-31 | ||
| 2022-12-31 | -$187.44K 10-K · filed 2024-02-26 | ||
| 2021-12-31 | -$8.10K 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |